Recurrent focal segmental glomerulosclerosis following renal transplantation in Korean pediatric patients

2001 ◽  
Vol 5 (2) ◽  
pp. 105-111 ◽  
Author(s):  
Sang Joon Kim ◽  
Jongwon Ha ◽  
In Mok Jung ◽  
Moon Sang Ahn ◽  
Minyoung Kim ◽  
...  
2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Christine Sethna ◽  
Corinne Benchimol ◽  
Hilary Hotchkiss ◽  
Rachel Frank ◽  
Lulette Infante ◽  
...  

Recurrence of focal segmental glomerulosclerosis (FSGS) after renal transplantation is a complication that often leads to graft loss. There is no consensus on the optimal treatment of recurrent FSGS. Rituximab, a monoclonal antibody to CD20, may be a useful treatment of this complication.Methods. We report four pediatric cases of recurrent FSGS treated with rituximab and plasmapheresis.Results. Four children (2M/2F), age 15.3 ± 2.6, with recurrent FSGS posttransplant were identified. Four doses of rituximab were administered 171 ± 180 days posttransplant and 114 ± 169 days after the start of plasmapheresis. Three children responded with complete remission, one of whom relapsed after four months. One child had a partial response with a decrease in proteinuria that was not sustained. No adverse side effects were reported during treatment or followup (mean 22.5 months).Conclusions. Rituximab is a safe and well-tolerated ancillary treatment for recurrent FSGS in pediatric patients in conjunction with plasmapheresis.


2006 ◽  
Vol 10 (8) ◽  
pp. 962-965 ◽  
Author(s):  
Kevin Couloures ◽  
Samuel H. Pepkowitz ◽  
Dennis Goldfinger ◽  
Elaine S. Kamil ◽  
Dechu P. Puliyanda

1991 ◽  
Vol 14 (2) ◽  
pp. 99-101 ◽  
Author(s):  
A.R. Datta ◽  
V. Sakhuja ◽  
M. Minz ◽  
K. Joshi ◽  
K.S. Chugh

Sign in / Sign up

Export Citation Format

Share Document